Joe Lennerz: The role of FGFR alterations in thyroid carcinoma
Joe Lennerz, Chief Scientific Officer at BostonGene, on LinkedIn:
“FGFR fusions in thyroid cancer are important because they can act as primary oncogenic drivers, provide potentially actionable therapeutic targets, have prognostic significance, contribute to resistance mechanisms, and support personalized medicine.
In this study, we investigated the role of FGFR alterations in thyroid carcinoma, identifying novel primary drivers and secondary events in tumor progression. Among 5,030 sequenced thyroid malignancies, 17 tumors exhibited FGFR alterations, with 11 driven by FGFR (n=9 gene fusions 4xFGFR2::VCL, 3xTG::FGFR1, FGFR2::CIT, FGFR2::SHTN1) or n=2 amplifications, and 6 showing FGFR as a secondary alteration.
These findings highlight the potential therapeutic implications of targeting FGFR alterations, which are currently under-recognized and may offer novel treatment options for thyroid cancer patients – especially in light of several very successful novel FGFR inhibitor strategies emerging in intrahepatic cholangiocarcinoma.
Great teamwork by Mark Sabbagh, Tyler Janovitz,Dora Dias-Santagata, Stephanie Siegmund, Valentina Nardi, Lori Wirth, gregory randolph, Brennan Decker, Vania Nose, Bayan Alzumaili, Bill Faquin, Justine Barletta, Long Phi Le, John Iafrate, Peter Sadow, and amazing leadership by Adam Fisch.”
Source: Joe Lennerz/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023